<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pityriasis rubra pilaris: Prognosis and management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pityriasis rubra pilaris: Prognosis and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pityriasis rubra pilaris: Prognosis and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Teri M Greiling, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristina Callis Duffin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1011498499"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pityriasis rubra pilaris (PRP) is a rare, inflammatory, cutaneous, papulosquamous disorder that has a variety of clinical presentations. PRP can cause pruritus, pain, inability to perform daily activities, and cosmetic disfigurement and can have a profound, negative impact on quality of life. Although spontaneous resolution is possible, PRP often persists for years.</p><p>Data on the treatment of PRP are limited, contributing to uncertainty regarding the best approach to treatment. Biologic agents, oral retinoids, and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> are the mainstays of treatment  (<a class="graphic graphic_algorithm graphicRef131839" href="/z/d/graphic/131839.html" rel="external">algorithm 1</a>).</p><p>The prognosis and management of PRP will be reviewed here. The pathogenesis, clinical manifestations, and diagnosis of PRP are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15283.html" rel="external">"Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H3632112582"><span class="h1">DISEASE OVERVIEW</span><span class="headingEndMark"> — </span>PRP may be sporadic or inherited, may occur in adults and children, and may exhibit a variety of clinical manifestations. PRP is often divided into six subtypes:</p><p class="bulletIndent1"><span class="glyph">●</span>Type I – Classical adult</p><p class="bulletIndent1"><span class="glyph">●</span>Type II – Atypical adult</p><p class="bulletIndent1"><span class="glyph">●</span>Type III – Classical juvenile</p><p class="bulletIndent1"><span class="glyph">●</span>Type IV – Circumscribed</p><p class="bulletIndent1"><span class="glyph">●</span>Type V – Atypical juvenile</p><p class="bulletIndent1"><span class="glyph">●</span>Type VI – HIV associated</p><p></p><p>Classical adult PRP is considered the most common clinical subtype. Common features of classical PRP include follicular, hyperkeratotic papules; waxy, yellow palmoplantar keratoderma; and erythroderma with islands of sparing  (<a class="graphic graphic_picture graphicRef86476 graphicRef86471 graphicRef86473 graphicRef86472 graphicRef86475 graphicRef86474 graphicRef131512 graphicRef131510 graphicRef131509 graphicRef131507 graphicRef131508" href="/z/d/graphic/86476.html" rel="external">picture 1A-K</a>). Limited, focal skin involvement with plaques studded with follicular plugs is characteristic of circumscribed PRP  (<a class="graphic graphic_picture graphicRef131515" href="/z/d/graphic/131515.html" rel="external">picture 2</a>). Ichthyosis-like changes and other features are present in atypical PRP  (<a class="graphic graphic_picture graphicRef131516" href="/z/d/graphic/131516.html" rel="external">picture 3</a>). (See  <a class="medical medical_review" href="/z/d/html/15283.html" rel="external">"Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical subtypes'</a> and  <a class="medical medical_review" href="/z/d/html/15283.html" rel="external">"Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H1303127002"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>PRP is not associated with systemic involvement or risk of mortality. However, morbidity and negative impact on quality of life are high. (See  <a class="medical medical_review" href="/z/d/html/15283.html" rel="external">"Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis", section on 'Psychosocial impact'</a>.)</p><p>PRP often persists for years. Spontaneous resolution can occur, but the time to resolution is unpredictable. Although associations between subtype and prognosis have been proposed (eg, classical PRP suggested to resolve more readily than atypical or circumscribed PRP) [<a href="#rid1">1</a>], these categories do not reliably predict the likelihood of spontaneous resolution or treatment response [<a href="#rid2">2-4</a>].</p><p>Spontaneous resolution is not typically abrupt. The natural course of disease for patients who experience spontaneous resolution appears to follow an initial, severe, inflammatory, and erythrodermic phase that persists for months, followed by slow and gradual improvement over the following years. Rapid resolution in less than one year appears to be more likely to occur in children than adults [<a href="#rid2">2,5</a>]. Recurrence of PRP after an initial remission is rare in adults but may be slightly more common in children [<a href="#rid6">6</a>].</p><p>Examples of studies of the prognosis of PRP include:</p><p class="bulletIndent1"><span class="glyph">●</span>In a survey study that included 45 adult and 5 pediatric patients recruited from two PRP support group websites who had an "unquestionable" diagnosis of PRP, the average duration of persistent symptoms among 32 adults with active disease at the time of enrollment was 67 months (range 2 to 484 months). The average time to symptom resolution for the 13 adults with resolved symptoms was 33 months (range 8 to 72 months) [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 57 patients (41 adults and 16 children) with PRP evaluated at a single center between 1929 and 1967, complete resolution occurred in 49 percent of patients at a mean of 2.3 years after symptom onset (range three months to seven years) [<a href="#rid5">5</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In various pediatric case series, the proportion of patients achieving near or complete resolution of childhood-onset PRP has been reported as 83 percent (with follow-up ranging from 1 to 20 years) [<a href="#rid2">2</a>], 43 percent (with follow-up period unspecified) [<a href="#rid6">6</a>], and 48 percent (with follow-up ranging from two months to nine years) [<a href="#rid8">8</a>]. </p><p></p><p class="headingAnchor" id="H3408704049"><span class="h1">TREATMENT PRINCIPLES</span><span class="headingEndMark"> — </span>Efficacy data for PRP are limited, and spontaneous resolution is possible, contributing to uncertainty about the best approach to treatment. Our approach is reviewed here; other approaches may be reasonable  (<a class="graphic graphic_algorithm graphicRef131839" href="/z/d/graphic/131839.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of treatment</strong> – Goals of treatment include the improvement of symptoms and achievement of long-term clinical remission of skin lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach</strong> – The approach to treatment generally consists of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin care measures and topical therapies to improve symptoms (see <a class="local">'Skin care'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Systemic treatment for PRP (see <a class="local">'Initial systemic treatment'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Patient support (see <a class="local">'Patient support'</a> below)</p><p></p><p class="bulletIndent1">Historically, oral retinoids and oral <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> have been regarded as the first-line systemic therapies for PRP. However, targeted biologic therapies are increasingly used for PRP, based upon clinical experience that suggests efficacy and lower risk of serious adverse effects. It is generally accepted that PRP does not respond well to oral glucocorticoids. (See <a class="local">'Initial systemic treatment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing response</strong> – An excellent response to treatment consists of near or complete resolution of skin lesions and associated symptoms. PRP is relatively slow to respond to systemic therapy. A two- to three-month medication trial is often necessary to assess efficacy prior to switching to an alternative therapy, and if significant improvement is noted by the clinician and patient, therapy should be continued for another two to three months before the full therapeutic response is achieved [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cessation of treatment</strong> – Patients who respond well to treatment may be able to discontinue treatment or may require continued therapy to remain in remission. We typically discontinue systemic therapy without a taper for patients who achieve complete remission, since in our experience, many patients will stay in remission off therapy. Systemic therapy can be restarted if signs of disease activity recur.</p><p></p><p class="bulletIndent1">In contrast, patients who have achieved only partial remission with treatment may be at greater risk for relapse following treatment cessation. In a study of 12 patients with PRP treated with <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>, all four patients who achieved 89 to 100 percent improvement in disease severity at the end of the 24-week treatment period remained in remission at week 36, whereas the three patients with 52 to 84 percent improvement worsened following discontinuation of ixekizumab [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H3657623707"><span class="h1">SKIN CARE</span><span class="headingEndMark"> — </span>Topical interventions may help to improve symptoms associated with skin lesions (eg, pain secondary to fissures). Emollients are the mainstay of topical treatment.</p><p class="headingAnchor" id="H335270659"><span class="h2">Emollients</span><span class="headingEndMark"> — </span>Emollients improve patient comfort by decreasing exfoliative scale and maintaining the skin barrier. We typically advise patients to apply a bland ointment, such as petrolatum, to all affected areas once to multiple times daily. Patients who dislike ointments may prefer bland, cream-based emollients. </p><p class="headingAnchor" id="H1910580133"><span class="h2">Keratolytic agents</span><span class="headingEndMark"> — </span>Urea 40% cream is helpful as a keratolytic for the palms and soles, especially for patients with thick keratoderma and fissuring. Hydrocolloid dressings provide comfort for palmoplantar fissures. (See  <a class="medical medical_review" href="/z/d/html/15283.html" rel="external">"Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis", section on 'Palmoplantar keratoderma'</a>.)</p><p class="headingAnchor" id="H60843109"><span class="h2">Topical corticosteroids</span><span class="headingEndMark"> — </span>Topical corticosteroids are often prescribed but whether topical corticosteroids are more effective than emollients is unclear. In a survey study, 19 of 38 patients (50 percent) treated with topical corticosteroids considered topical corticosteroids helpful compared with 34 of 45 patients (76 percent) treated with emollients [<a href="#rid7">7</a>]. </p><p>A reasonable approach to topical corticosteroid therapy consists of a two-week trial of a medium-potency (eg, group 4) topical corticosteroid applied daily to affected areas on the trunk or extremities; lower-potency (eg, groups 6 or 7) topical corticosteroids are used for the face and intertriginous skin  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 1</a>). If the patient does not have significant improvement within two weeks, the corticosteroid should be discontinued.</p><p class="headingAnchor" id="H624052270"><span class="h1">INITIAL SYSTEMIC TREATMENT</span></p><p class="headingAnchor" id="H2106151225"><span class="h2">Patient selection</span><span class="headingEndMark"> — </span>Systemic therapy plays an important role in the treatment of most patients with PRP and is typically started promptly for adults with widespread or highly symptomatic PRP. An initial trial of topical therapy alone is an alternative initial approach for patients with limited or circumscribed PRP  (<a class="graphic graphic_algorithm graphicRef131839" href="/z/d/graphic/131839.html" rel="external">algorithm 1</a>).</p><p>A more conservative approach is sometimes taken for children with PRP. (See <a class="local">'Children'</a> below.)</p><p class="headingAnchor" id="H1995673897"><span class="h2">Treatment selection</span><span class="headingEndMark"> — </span>Injectable biologic inhibitors of the interleukin (IL) 17 or IL-23 pathway are our preferred first-line systemic therapies for adults and children with PRP  (<a class="graphic graphic_algorithm graphicRef131839" href="/z/d/graphic/131839.html" rel="external">algorithm 1</a>). Oral retinoids and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> are alternative initial therapies with a long history of use for PRP.</p><p>Data are insufficient for conclusions on the relative efficacy of oral retinoids and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> compared with biologic therapy. Our preference for biologic therapy is based upon the more favorable side effect profile and the limited available data that suggest efficacy of biologic anti-IL-17 and anti-IL-23 therapies. Other clinicians advocate for the initial use of nonbiologic therapies [<a href="#rid11">11,12</a>].</p><p class="headingAnchor" id="H976417055"><span class="h2">IL-17 inhibitors</span><span class="headingEndMark"> — </span>The IL-17 inhibitors (<a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>, <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, and <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a>) may be beneficial for PRP. Ixekizumab and secukinumab inhibit IL-17A. Brodalumab blocks the IL-17 receptor A. Expression of IL-17A, a proinflammatory cytokine, appears to be upregulated in skin from patients with PRP [<a href="#rid13">13</a>] (see  <a class="medical medical_review" href="/z/d/html/15283.html" rel="external">"Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis", section on 'Pathogenesis'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Studies directly comparing the efficacy of individual IL-17 inhibitors for PRP are lacking. We consider <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>, <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, and <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a> all appropriate choices for initial therapy for adults with PRP.</p><p></p><p class="bulletIndent1">Our preferred IL-17 inhibitors for children are <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a> and <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, based upon pediatric data that support efficacy and safety of these drugs for psoriasis in children. Ixekizumab and secukinumab are US Food and Drug Administration (FDA) approved for the treatment of psoriasis in children age six years and older. (See  <a class="medical medical_review" href="/z/d/html/112983.html" rel="external">"Psoriasis in children: Management of chronic plaque psoriasis", section on 'Biologic agents'</a>.)</p><p></p><p class="bulletIndent1">Treatment regimens for PRP typically mimic the regimens used for psoriasis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adults</strong>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">Ixekizumab</a>: 160 mg at week 0; 80 mg at weeks 2, 4, 6, 8, 10, and 12; then 80 mg every four weeks</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">Secukinumab</a>: 300 mg once weekly at weeks 0, 1, 2, 3, and 4, then 300 mg every four weeks</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">Brodalumab</a>: 210 mg at weeks 0, 1, and 2, then 210 mg once every two weeks</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children</strong>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">Ixekizumab</a>: weight-based dosing; for children &lt;25 kg, 40 mg at week 0, then 20 mg every four weeks; for children 25 to 50 kg, 80 mg at week 0, then 40 mg every four weeks; for children &gt;50 kg, 160 mg at week 0, then 80 mg every four weeks</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">Secukinumab</a>: weight-based dosing; for children &lt;50 kg, 75 mg at weeks 0, 1, 2, 3, and 4, then 75 mg every four weeks; for children ≥50 kg, 150 mg at weeks 0, 1, 2, 3, and 4, then 150 mg every four weeks</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Efficacy data for IL-17 inhibitors are limited to single-arm studies. In an open-label study in which 12 adults with moderate to severe PRP (including 11 who failed at least one other systemic therapy) were treated with <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a> for 24 weeks, seven (58 percent) achieved at least a 50 percent reduction in clinician-assessed severity (as measured by the Psoriasis Area and Severity Index [PASI]) [<a href="#rid10">10</a>]. The mean time to improvement was approximately seven weeks, and the median itch score on a 10-point numeric rating scale (with 10 being the worst itch and 0 being no itch) decreased from 7 to 1 over the treatment period. There were no serious or unexpected adverse events. Furthermore, ixekizumab led to normalization in gene expression of IL-17A and other dysregulated genes in the skin after 24 weeks [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">Another open-label study assessed outcomes of 24 weeks of <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> therapy in 12 patients with adult-onset PRP and at least 10 percent body surface area involvement [<a href="#rid15">15</a>]. All patients had a history of failure to respond to topical corticosteroids and at least one systemic agent. At week 28, rates of 50, 75, or 90 percent improvement in the PASI score among the 11 patients available for outcome assessment were 73, 55, and 27 percent, respectively. In addition, ribonucleic acid (RNA) sequencing performed after two weeks of secukinumab therapy revealed improvement in the gene expression patterns in lesional skin. </p><p></p><p class="bulletIndent1">In addition, multiple case reports and case series report improvement with IL-17 inhibitor therapy in patients with PRP, including PRP resistant to other therapies and familial PRP. These reports describe benefit from <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a> [<a href="#rid16">16-21</a>], <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> [<a href="#rid22">22-28</a>], and <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a> [<a href="#rid29">29-31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Side effects of IL-17 inhibitors can include injection site reactions and an increased risk of upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infection. There is a rare risk of inflammatory bowel disease. <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">Brodalumab</a> also carries a United States boxed warning for suicidal ideation and behavior. (See  <a class="drug drug_general" href="/z/d/drug information/107448.html" rel="external">"Ixekizumab: Drug information"</a> and  <a class="drug drug_general" href="/z/d/drug information/99569.html" rel="external">"Secukinumab: Drug information"</a> and  <a class="drug drug_general" href="/z/d/drug information/112051.html" rel="external">"Brodalumab: Drug information"</a>.)</p><p></p><p class="headingAnchor" id="H4247582265"><span class="h2">IL-23 inhibitors</span><span class="headingEndMark"> — </span>IL-23 inhibitors used for PRP include <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, which inhibits the p40 subunit of IL-12 and IL-23; <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">risankizumab</a>, and <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a> target the p19 subunit of IL-23. The IL-23/Th17 axis is thought to play an important role in the pathogenesis of PRP [<a href="#rid13">13</a>] (see  <a class="medical medical_review" href="/z/d/html/15283.html" rel="external">"Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis", section on 'Pathogenesis'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Studies directly comparing the efficacy of individual IL-23 inhibitors for PRP are lacking. We consider <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">risankizumab</a>, and <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a> all appropriate choices for initial therapy for adults with PRP.</p><p></p><p class="bulletIndent1">Our preferred IL-23 inhibitor for children is <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, based upon pediatric data that support efficacy and safety for psoriasis in children. Ustekinumab is FDA approved for the treatment of psoriasis in children six years of age and older. (See  <a class="medical medical_review" href="/z/d/html/112983.html" rel="external">"Psoriasis in children: Management of chronic plaque psoriasis", section on 'Biologic agents'</a>.)</p><p></p><p class="bulletIndent1">Treatment regimens for PRP typically mimic regimens used for psoriasis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adults</strong>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a>: Adults ≤100 kg is 45 mg given at weeks 0, 4, and every 12 weeks thereafter. A 90 mg dose given in the same regimen is recommended for adults who weigh more than 100 kg.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">Guselkumab</a>: 100 mg at weeks 0, 4, and then every 8 weeks.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">Risankizumab</a>: 150 mg at week 0 and week 4, then every 12 weeks.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">Tildrakizumab</a>: 100 mg at week 0 and week 4, then every 12 weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children</strong>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a>: weight-based dosing; for children ≤60 kg, 0.75 mg/kg; for children &gt;60 to ≤100 kg, 45 mg; for children &gt;100 kg, 90 mg; ustekinumab is given at weeks 0, 4, then every 12 weeks</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – There are multiple reports of benefit of IL-23 inhibitors in PRP. However, data are limited to case reports, and the efficacy rate of these agents for PRP remains unclear. A systematic review of reports of systemic therapy for PRP found documentation suggestive of an excellent response in 10 of 16 patients (63 percent) treated with <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, with an average time to therapeutic response of six weeks [<a href="#rid9">9</a>]. Another systematic review of reports documenting responses of type 1 PRP to various therapies found documentation consistent with a "very good response" in 12 of 17 patients (71 percent) treated with ustekinumab, with improvement noted within the first four weeks [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1">In addition, a survey study of patient-reported outcomes with IL-23 inhibitors found that 48 of 80 patients (60 percent) who had received <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> or <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a> described their outcomes as "complete clearance" or "substantial improvement" [<a href="#rid32">32</a>]. Response rates were similar in the subset of pediatric patients, with 8 out of 12 juvenile survey respondents (67 percent) reporting "substantial improvement" with ustekinumab.</p><p></p><p class="bulletIndent1">Case reports describe successful treatment of refractory PRP with <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">risankizumab</a> [<a href="#rid33">33-35</a>] and <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a> [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects of IL-23 inhibition can include hypersensitivity reactions and infections, although the risk of serious adverse events is not significantly different from placebo in meta-analyses of psoriasis trials [<a href="#rid37">37</a>]. (See  <a class="drug drug_general" href="/z/d/drug information/9514.html" rel="external">"Ustekinumab (including biosimilars): Drug information"</a> and  <a class="drug drug_general" href="/z/d/drug information/114007.html" rel="external">"Guselkumab: Drug information"</a> and  <a class="drug drug_general" href="/z/d/drug information/121112.html" rel="external">"Risankizumab: Drug information"</a>.)</p><p></p><p class="headingAnchor" id="H4022031969"><span class="h2">Alternative initial therapies</span><span class="headingEndMark"> — </span>Oral retinoids and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> are alternative initial therapies  (<a class="graphic graphic_algorithm graphicRef131839" href="/z/d/graphic/131839.html" rel="external">algorithm 1</a>). The efficacy of oral retinoids and methotrexate has not been compared in randomized trials, contributing to uncertainty regarding relative efficacy.</p><p>We typically use the oral retinoid <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> for initial treatment when patients cannot obtain or tolerate biologic therapy [<a href="#rid9">9</a>]. We reserve initial treatment with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> for patients who cannot obtain or tolerate biologic or oral retinoid therapy.<strong> </strong>In a systematic review of published reports documenting systemic therapy for PRP, excellent responses were reported more frequently with isotretinoin than with methotrexate (61 percent of 167 patients versus 33 percent of 160 patients) [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H512195688"><span class="h3">Oral retinoids</span><span class="headingEndMark"> — </span>Oral retinoids, such as <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a>, and etretinate, may be beneficial for PRP. Alitretinoin and etretinate are not available in the United States. We typically treat with isotretinoin. Our preference for isotretinoin over acitretin is based upon clinical experience that suggests greater efficacy of isotretinoin for PRP [<a href="#rid9">9</a>]. </p><p>Caution is indicated for oral retinoid therapy in individuals of childbearing potential. Oral retinoids are teratogenic, and pregnancy must be avoided during therapy and for specific periods following the cessation of therapy (see  <a class="drug drug_general" href="/z/d/drug information/9250.html" rel="external">"Acitretin: Drug information"</a> and  <a class="drug drug_general" href="/z/d/drug information/8582.html" rel="external">"Isotretinoin: Drug information"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The best dosing regimens for oral retinoid therapy for PRP are unclear. We typically treat with <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, starting at 0.5 mg/kg per day and increase to 1 mg/kg per day after one month provided the patient is tolerating therapy. <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> is often given at a dose of 0.5 mg/kg per day. Signs of improvement are expected within two months. (See <a class="local">'Treatment principles'</a> above.)</p><p></p><p class="bulletIndent1">Early reports of use in PRP suggested that higher doses may be more effective, but this must be balanced with increased risk for adverse effects. For example, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> was given at an average dose of 2.13 mg/kg, with maximum doses over 3 mg/kg/day in a case series that reported 43 of 45 patients as "clearly improved" [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The relative efficacy of individual oral retinoids is unclear. <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">Alitretinoin</a> and <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> were associated with higher proportions of excellent responses compared with <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> and etretinate in a systematic review of case reports and retrospective case series [<a href="#rid9">9</a>]. Excellent responses were achieved in 73 percent of patients for alitretinoin, 61 percent for isotretinoin, 47 percent for etretinate, and 25 percent for acitretin.</p><p></p><p class="bulletIndent1">Another systematic review of reports of therapies for type I PRP found documentation supportive of a "very good response" in 27 of 75 patients (36 percent) treated with <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> as monotherapy and 19 of 23 patients (83 percent) treated with acitretin plus biologic therapy [<a href="#rid11">11</a>]. In a survey study that included 32 patients with PRP treated with oral retinoids, 19 patients (59 percent) described oral retinoids as "helpful" [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Common side effects of oral retinoids include dry skin, cheilitis, headache, alopecia, and increased serum cholesterol and triglyceride levels. These adverse effects tend to be dose dependent. In a systematic review of reports of systemic therapy for PRP, adverse events occurred in 34 percent of patients treated with oral retinoids, a rate higher than reported for other therapies [<a href="#rid9">9</a>]. Laboratory monitoring for oral retinoids is reviewed separately. (See  <a class="drug drug_general" href="/z/d/drug information/9250.html" rel="external">"Acitretin: Drug information"</a> and  <a class="drug drug_general" href="/z/d/drug information/8582.html" rel="external">"Isotretinoin: Drug information"</a>.)</p><p></p><p class="bulletIndent1">In addition, oral retinoids are teratogenic and must be used with caution in individuals. For <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, pregnancy should be avoided during treatment and for the following three years; therefore, use of acitretin in individuals of childbearing potential is generally avoided. Pregnancy should be avoided during and for one month following <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy. In the United States, isotretinoin can only be prescribed through the iPLEDGE risk evaluation and mitigation strategy (REMS) program. (See  <a class="drug drug_general" href="/z/d/drug information/9250.html" rel="external">"Acitretin: Drug information"</a> and  <a class="drug drug_general" href="/z/d/drug information/8582.html" rel="external">"Isotretinoin: Drug information"</a>.)</p><p></p><p class="headingAnchor" id="H896245682"><span class="h3">Methotrexate</span><span class="headingEndMark"> — </span>Low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> may be beneficial for PRP. The antiproliferative and anti-inflammatory effects of methotrexate are proposed to contribute to benefit [<a href="#rid12">12</a>].</p><p>Certain comorbidities can inhibit the use of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> in some patients. Caution is indicated for patients with hepatic impairment or renal insufficiency. Methotrexate is contraindicated in pregnancy, and caution is also indicated when treating individuals of childbearing potential. Avoidance of alcohol consumption is recommended during treatment:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> may be given orally or subcutaneously. Dosing for adults is usually 10 to 25 mg given once <strong>weekly</strong>.</p><p></p><p class="bulletIndent1">Most adults can be started at 15 mg once weekly and increased up to 25 mg weekly, as tolerated, after the first month. Dose adjustments are indicated for patients with renal dysfunction. Subcutaneous administration may be beneficial for patients requiring more than 15 mg per week, as this may optimize drug absorption and minimize gastrointestinal side effects. Clinical improvement is expected within three months [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Absorption and route of administration'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">Folic acid</a> should be administered during <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> therapy to reduce risk for adverse effects. A typical dose of folic acid is 1 mg per day. Laboratory monitoring for adverse effects of methotrexate is also indicated. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Folic acid supplementation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Support for the use of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> stems from case reports and case series. A systematic review of the literature published from 1964 to 2017 that identified a total of 116 patients treated with methotrexate alone or in combination with other systemic therapies found documentation consistent with total clearance or excellent improvement in 23 and 17 percent of patients, respectively [<a href="#rid12">12</a>]. Other systematic reviews of reports of methotrexate for PRP have identified documentation of either "excellent" or "very good" responses in approximately one-third of the reported patients [<a href="#rid9">9,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Common side effects of low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> include headache; nausea; and mild, transient elevations in liver transaminases. Uncommon, serious adverse reactions include bone marrow suppression, severe liver injury, interstitial pneumonitis, and hepatotoxicity. Methotrexate is contraindicated in pregnancy. Laboratory monitoring for methotrexate is reviewed separately. (See  <a class="drug drug_general" href="/z/d/drug information/9630.html" rel="external">"Methotrexate: Drug information"</a>.)</p><p></p><p class="headingAnchor" id="H455139465"><span class="h1">REFRACTORY DISEASE</span><span class="headingEndMark"> — </span>Data are insufficient for conclusions on the best course following treatment failure. Responses to biologic therapies following failure of retinoids, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, or other biologic therapies have been reported [<a href="#rid10">10,32</a>]. (See <a class="local">'Treatment principles'</a> above.)</p><p>Our general approach to failure of initial treatment is as follows  (<a class="graphic graphic_algorithm graphicRef131839" href="/z/d/graphic/131839.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insufficient response to biologic IL-17 or IL-23 inhibitor</strong> – Switch to different class of biologic drug (eg, switch from anti-interleukin [IL] 17 drug to anti-IL-23 drug or vice versa) or add oral retinoid or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> to biologic therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insufficient response to oral retinoid or </strong><strong>methotrexate</strong> – Switch to anti-IL-17 or anti-IL-23 biologic drug </p><p></p><p>Additional options for the treatment of PRP include biologic tumor necrosis factor (TNF)-alpha inhibitors, phototherapy, and other therapies. (See <a class="local">'Other therapies'</a> below.)</p><p class="headingAnchor" id="H2742736992"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H1963853647"><span class="h2">Children</span><span class="headingEndMark"> — </span>Topical therapy is generally preferred for the management of circumscribed PRP in children. However, functionally limiting disease (eg, significant involvement of the palms and soles) may prompt use of systemic treatment. (See <a class="local">'Skin care'</a> above and <a class="local">'Initial systemic treatment'</a> above.)</p><p>Similar to adults, children with extensive skin involvement, such as that occurs in classical PRP, are candidates for systemic therapy. As spontaneous improvement may be more likely in children than adults, the degree to which symptoms impact the child's quality of life plays a role in the decision to initiate systemic treatment. (See <a class="local">'Prognosis'</a> above and <a class="local">'Initial systemic treatment'</a> above.)</p><p class="headingAnchor" id="H2993740793"><span class="h2">HIV-associated pityriasis rubra pilaris</span><span class="headingEndMark"> — </span>Treatment of HIV-associated PRP can be challenging, and data on treatment efficacy are limited. Improvement in HIV-associated PRP with triple antiretroviral therapy (<a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> [AZT], <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a>, and <a class="drug drug_general" data-topicid="9877" href="/z/d/drug information/9877.html" rel="external">saquinavir</a>) was documented in a case report [<a href="#rid39">39</a>]. Other reports document variable responses to AZT, oral retinoids, and phototherapy [<a href="#rid40">40</a>].</p><p>Successful treatment in the absence of antiretroviral therapy has not been reported. A reasonable initial approach is antiretroviral therapy for HIV infection, with the addition of systemic therapy for PRP if improvement does not occur. Oral retinoids are generally used because of a lack of immunosuppressive effects. Cautious use of systemic immunomodulatory therapies for PRP may be an additional option for patients with severe, symptomatic PRP.</p><p class="headingAnchor" id="H631675897"><span class="h2"><i>CARD14</i>-associated papulosquamous eruption</span><span class="headingEndMark"> — </span><em>CARD14</em>-associated papulosquamous eruption (CAPE) is an entity first described in 2018 and defined by the presence of psoriasis-like and/or PRP-like skin manifestations in patients with <em>CARD14</em> gene mutations. A case series and case report suggest benefit of <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> [<a href="#rid41">41,42</a>]. In a study of 15 kindreds with CAPE, five of six patients achieved a near complete response, and one patient had a partial response to ustekinumab therapy [<a href="#rid41">41</a>].</p><p>Responses to conventional topical and systemic therapies used for psoriasis were minimal in the study of 15 kindreds. In contrast, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> therapy was associated with near complete clearance of skin lesions in a young child with CAPE [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H3297473761"><span class="h1">OTHER THERAPIES</span><span class="headingEndMark"> — </span>Additional therapies that may have efficacy for PRP include tumor necrosis factor (TNF)-alpha inhibitors, phototherapy, and other therapies.</p><p class="headingAnchor" id="H3145759074"><span class="h2">TNF-alpha inhibitors</span><span class="headingEndMark"> — </span>Biologic tumor necrosis factor (TNF)-alpha inhibitors, such as <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, have been reported as beneficial for PRP. Although TNF-alpha inhibitors were the first biologic agents used in the treatment of PRP, recognition of an important role for the interleukin (IL) 23/IL-17 axis in PRP has contributed to increased use of biologic IL-17 and IL-23 inhibitors for PRP. (See  <a class="medical medical_review" href="/z/d/html/15283.html" rel="external">"Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis", section on 'Pathogenesis'</a> and <a class="local">'IL-17 inhibitors'</a> above and <a class="local">'IL-23 inhibitors'</a> above.)</p><p>As with other therapies, data on efficacy are derived from case reports and case series [<a href="#rid9">9,11,44</a>]. One systematic review of published reports of systemic therapy for PRP identified documentation consistent with an excellent response in 28 of 49 patients (57 percent) given <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, 16 of 30 patients (53 percent) given <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, and 13 of 28 patients (46 percent) given <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> [<a href="#rid9">9</a>]. In a survey study that included 132 patients treated with TNF-alpha inhibitors, 10 and 35 percent of patients reported complete clearance and substantial improvement, respectively [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H167609761"><span class="h2">Phototherapy</span><span class="headingEndMark"> — </span>Phototherapy in the form of psoralens with ultraviolet A (PUVA) or narrowband ultraviolet B (NBUVB) is more often reported to be ineffective or cause exacerbation of PRP, although there are occasional case reports of treatment success, especially in combination with <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> [<a href="#rid11">11</a>]. In a retrospective survey, only 1 of 13 patients with PRP found phototherapy helpful [<a href="#rid7">7</a>]. We do not typically use phototherapy for PRP.</p><p>It has been proposed that the type of phototherapy may be relevant. In a case report, a patient, in whom phototesting revealed exacerbation of skin disease following ultraviolet B (UVB) but not ultraviolet A (UVA), achieved sustained remission following treatment with bath PUVA [<a href="#rid45">45,46</a>]. (See  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a>.)</p><p class="headingAnchor" id="H1463999845"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>Examples of other therapies for which benefit for PRP has been reported in case reports or case series but are less frequently used for this indication include <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, fumaric acid esters, intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a>, and <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> [<a href="#rid9">9,11</a>]. An advantage of cyclosporine is the rapid onset of action (often within one month). However, cyclosporine is associated with risk for serious adverse effects, and a systematic review of published reports of systemic therapy for PRP found documentation of an "excellent" response in only 12 percent of patients treated with cyclosporine [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H299422821"><span class="h1">PATIENT SUPPORT</span><span class="headingEndMark"> — </span>PRP can have a profound, negative psychologic impact, which should be supported and treated alongside the skin manifestations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Support from other patients</strong> – Referral to support groups, such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fprpalliance.com%2F&amp;token=kV9xQ9YNoTUTAoIzWjeuyp%2BrfEOyW15C0G1l1%2BHVr%2F6vALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=131425" target="_blank">PRP Alliance</a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.rareconnect.org%2Fen%2Fcommunity%2Fpityriasis-rubra-pilaris&amp;token=UUD3ShLzzj5vSNnEZy9Jh0DdGGU60%2BNMEC4vYechQtGzvn6tTtuCaBUOJrfQU2WLkjnObqIx%2FOpXsiLE7mowbiE7Ux4SwBhdUjWqLXVUB5U%3D&amp;TOPIC_ID=131425" target="_blank">RareConnect</a>, may be beneficial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Support for mental health</strong> – Disease-related depression appears to be common in PRP, and even suicidality may not be uncommon among patients with moderate to severe PRP [<a href="#rid7">7,47</a>]. Patients experiencing such symptoms should be assessed and referred to a mental health professional. (See  <a class="medical medical_review" href="/z/d/html/15283.html" rel="external">"Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis", section on 'Psychosocial impact'</a>.)</p><p></p><p class="headingAnchor" id="H3191009066"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Pityriasis rubra pilaris (PRP) is a rare, cutaneous, papulosquamous disorder that can negatively affect quality of life. The prognosis of PRP is variable and unpredictable; PRP may spontaneously resolve within a few years or exhibit a prolonged course. (See <a class="local">'Disease overview'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment principles</strong> – The major treatment goals for PRP are improvement of symptoms and the achievement of long-term remission. Typical components of treatment include skin care with topical therapies to improve patient comfort (eg, emollients and keratolytics), systemic treatment, and patient support  (<a class="graphic graphic_algorithm graphicRef131839" href="/z/d/graphic/131839.html" rel="external">algorithm 1</a>). (See <a class="local">'Treatment principles'</a> above and <a class="local">'Skin care'</a> above.)</p><p></p><p class="bulletIndent1">Systemic therapy is appropriate for patients with widespread or highly symptomatic PRP. The response to systemic treatment tends to be delayed, often requiring at least two to three months of treatment prior to assessing for response. (See <a class="local">'Treatment principles'</a> above and <a class="local">'Initial systemic treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial systemic therapy</strong> – Biologic interleukin (IL) 17 inhibitors, biologic IL-23 inhibitors, oral retinoids, and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> are the mainstays of initial systemic treatment  (<a class="graphic graphic_algorithm graphicRef131839" href="/z/d/graphic/131839.html" rel="external">algorithm 1</a>). (See <a class="local">'Treatment selection'</a> above.)</p><p></p><p class="bulletIndent1">For patients who require systemic therapy, we suggest a biologic IL-17 or IL-23 inhibitor as initial therapy, rather than oral retinoid or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This preference is based upon the more favorable side effect profile of these biologic therapies. (See <a class="local">'IL-17 inhibitors'</a> above and <a class="local">'IL-23 inhibitors'</a> above.)</p><p></p><p class="bulletIndent1">For patients who cannot obtain or tolerate biologic therapy, we suggest oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> rather than <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> for initial treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Efficacy of these drugs has not been directly compared. However, review of data from case reports and case series suggest isotretinoin may be more likely to be effective for PRP. (See <a class="local">'Alternative initial therapies'</a> above.)</p><p></p><p class="bulletIndent1">For patients who cannot obtain or tolerate a biologic agent or oral retinoids, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> is appropriate for initial treatment. (See <a class="local">'Alternative initial therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient support</strong> – PRP can have a profound, negative impact on quality of life. Some patients may find patient support groups or referral to a mental health professional helpful. (See <a class="local">'Patient support'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cessation of treatment</strong> – Continuation of treatment is not always necessary to maintain remission. Treatment can be discontinued for patients who achieve clinical remission. Treatment can be restarted if signs of disease activity recur. (See <a class="local">'Treatment principles'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol 1980; 5:105.</a></li><li><a class="nounderline abstract_t">Gelmetti C, Schiuma AA, Cerri D, Gianotti F. Pityriasis rubra pilaris in childhood: a long-term study of 29 cases. Pediatr Dermatol 1986; 3:446.</a></li><li><a class="nounderline abstract_t">Piamphongsant T, Akaraphant R. Pityriasis rubra pilaris: a new proposed classification. Clin Exp Dermatol 1994; 19:134.</a></li><li><a class="nounderline abstract_t">Griffiths WA. Pityriasis rubra pilaris: the problem of its classification. J Am Acad Dermatol 1992; 26:140.</a></li><li><a class="nounderline abstract_t">Davidson CL Jr, Winkelmann RK, Kierland RR. Pityriasis rubra pilaris. A follow-up study of 57 patients. Arch Dermatol 1969; 100:175.</a></li><li><a class="nounderline abstract_t">Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH. Pityriasis rubra pilaris in children. J Am Acad Dermatol 2002; 47:386.</a></li><li><a class="nounderline abstract_t">Ross NA, Chung HJ, Li Q, et al. Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra Pilaris: A Case Series of 100 Patients. JAMA Dermatol 2016; 152:670.</a></li><li><a class="nounderline abstract_t">Yang CC, Shih IH, Lin WL, et al. Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan. J Am Acad Dermatol 2008; 59:943.</a></li><li><a class="nounderline abstract_t">Kromer C, Sabat R, Celis D, Mössner R. Systemic therapies of pityriasis rubra pilaris: a systematic review. J Dtsch Dermatol Ges 2019; 17:243.</a></li><li><a class="nounderline abstract_t">Haynes D, Strunck JL, Topham CA, et al. Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial. JAMA Dermatol 2020; 156:668.</a></li><li><a class="nounderline abstract_t">Engelmann C, Elsner P, Miguel D. Treatment of pityriasis rubra pilaris type I: a systematic review. Eur J Dermatol 2019; 29:524.</a></li><li><a class="nounderline abstract_t">Koch L, Schöffl C, Aberer W, Massone C. Methotrexate Treatment for Pityriasis Rubra Pilaris: A Case Series and Literature Review. Acta Derm Venereol 2018; 98:501.</a></li><li><a class="nounderline abstract_t">Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. JAMA Dermatol 2017; 153:304.</a></li><li><a class="nounderline abstract_t">Haynes D, Reiter T, Velasco R, et al. Pityriasis Rubra Pilaris Transcriptomics Implicate T Helper 17 Signaling and Correlate with Response to Ixekizumab, with Distinct Gene Expression Profiles in Nonresponders. J Invest Dermatol 2023; 143:501.</a></li><li><a class="nounderline abstract_t">Boudreaux BW, Pincelli TP, Bhullar PK, et al. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. Br J Dermatol 2022; 187:650.</a></li><li><a class="nounderline abstract_t">Richey PM, Fairley JA, Stone MS. Transformation from pityriasis rubra pilaris to erythema gyratum repens-like eruption without associated malignancy: A report of 2 cases. JAAD Case Rep 2018; 4:944.</a></li><li><a class="nounderline abstract_t">Penalba-Torres M, Pinilla-Martín B, Aragón-Miguel R, et al. Successful treatment of resistant pityriasis rubra pilaris with ixekizumab. Dermatol Ther 2020; 33:e13644.</a></li><li><a class="nounderline abstract_t">Chastagner M, Hoelt P, Kanitakis J, et al. Successful treatment of TNFα inhibitor-resistant pityriasis rubra pilaris with ixekizumab and acitretin. Eur J Dermatol 2019; 29:218.</a></li><li><a class="nounderline abstract_t">Heibel MD, Heibel HD. Successful treatment of type I pityriasis rubra pilaris with ixekizumab. JAAD Case Rep 2018; 4:774.</a></li><li><a class="nounderline abstract_t">Hanfstingl K, Pekar-Lukacs A, Motz R, et al. Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab. Case Rep Dermatol 2018; 10:97.</a></li><li><a class="nounderline abstract_t">Kohn D, Wetzig T. [Pityriasis rubra pilaris : Successful treatment with ixekizumab]. Hautarzt 2020; 71:624.</a></li><li><a class="nounderline abstract_t">Papini M, Russo A, Natalini Y, et al. Secukinumab is an effective and safe treatment for refractory pityriasis rubra pilaris. Ital J Dermatol Venerol 2021; 156:501.</a></li><li><a class="nounderline abstract_t">Liang JY, Ye RX, Tian X, et al. Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review. Dermatol Ther 2020; 33:e14097.</a></li><li><a class="nounderline abstract_t">Cole D, Mohammad T, Lim H. Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab. Br J Dermatol 2019; 181:1331.</a></li><li><a class="nounderline abstract_t">Wain T, Choy B, Satchell AC, et al. Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasets. JAAD Case Rep 2018; 4:500.</a></li><li><a class="nounderline abstract_t">Bonomo L, Levitt JO. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris. Cutis 2018; 101:367.</a></li><li><a class="nounderline abstract_t">Gauci ML, Jachiet M, Gottlieb J, et al. Successful treatment of type II pityriasis rubra pilaris with secukinumab. JAAD Case Rep 2016; 2:462.</a></li><li><a class="nounderline abstract_t">Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, Schempp CM. Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab. JAMA Dermatol 2016; 152:1278.</a></li><li><a class="nounderline abstract_t">Amat-Samaranch V, Cubiró X, Tubau C, et al. Response of pityriasis rubra pilaris to brodalumab after primary failure to ustekinumab. Int J Dermatol 2021; 60:e112.</a></li><li><a class="nounderline abstract_t">De Felice C, Graceffa D, Morrone A, Bonifati C. Familial pityriasis rubra pilaris successfully treated with brodalumab. Int J Dermatol 2020; 59:885.</a></li><li><a class="nounderline abstract_t">De Rosa A, Gambardella A, Licata G, et al. Successful treatment of Pityriasis rubra pilaris with brodalumab. Australas J Dermatol 2020; 61:e249.</a></li><li><a class="nounderline abstract_t">Maloney NJ, Kim MM, Nguyen KA, et al. Patient experiences with biologics and apremilast in pityriasis rubra pilaris: A patient survey. Dermatol Ther 2019; 32:e13060.</a></li><li><a class="nounderline abstract_t">Ricar J, Cetkovska P. Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab. Br J Dermatol 2021; 184:e148.</a></li><li><a class="nounderline abstract_t">Kromer C, Schön MP, Mössner R. Treatment of pityriasis rubra pilaris with risankizumab in two cases. J Dtsch Dermatol Ges 2021; 19:1207.</a></li><li><a class="nounderline abstract_t">Brocco E, Laffitte E. Risankizumab for pityriasis rubra pilaris. Clin Exp Dermatol 2021; 46:1322.</a></li><li><a class="nounderline abstract_t">Licata G, Gambardella A, Calabrese G, et al. Refractory Type I pityriasis rubra pilaris treated with tildrakizumab. Clin Exp Dermatol 2021; 46:1594.</a></li><li><a class="nounderline abstract_t">Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2020; 1:CD011535.</a></li><li><a class="nounderline abstract_t">Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol 1982; 6:710.</a></li><li><a class="nounderline abstract_t">González-López A, Velasco E, Pozo T, Del Villar A. HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy. Br J Dermatol 1999; 140:931.</a></li><li><a class="nounderline abstract_t">Miralles ES, Núñez M, De Las Heras ME, et al. Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol 1995; 133:990.</a></li><li><a class="nounderline abstract_t">Craiglow BG, Boyden LM, Hu R, et al. CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. J Am Acad Dermatol 2018; 79:487.</a></li><li><a class="nounderline abstract_t">Nieto-Benito LM, Baniandrés-Rodríguez O, Moreno-Torres A, et al. Clinical response to ustekinumab in CARD14-associated papulosquamous eruption (CAPE) with a new missense mutation in CARD14: a case report and systematic review. J Eur Acad Dermatol Venereol 2020; 34:e728.</a></li><li><a class="nounderline abstract_t">Wong GHZ, Chia SY, Wei H, et al. CARD14-associated papulosquamous eruption (CAPE) in a toddler responding to treatment with acitretin. Pediatr Dermatol 2021; 38:970.</a></li><li><a class="nounderline abstract_t">Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: A review of the literature. J Am Acad Dermatol 2018; 79:353.</a></li><li><a class="nounderline abstract_t">Kaskel P, Grundmann-Kollmann M, Schiller PI, et al. Bath-PUVA as a treatment for Pityriasis rubra pilaris provoked by ultraviolet B. Br J Dermatol 1999; 140:769.</a></li><li><a class="nounderline abstract_t">Kaskel P, Peter RU, Kerscher M. Phototesting and phototherapy in pityriasis rubra pilaris. Br J Dermatol 2001; 144:430.</a></li><li><a class="nounderline abstract_t">Ji-Xu A, Lei DK, Worswick S, et al. Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris. Br J Dermatol 2022; 187:1024.</a></li></ol></div><div id="topicVersionRevision">Topic 131425 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7398119" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3562357" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pityriasis rubra pilaris in childhood: a long-term study of 29 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8050142" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pityriasis rubra pilaris: a new proposed classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732330" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pityriasis rubra pilaris: the problem of its classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5797957" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pityriasis rubra pilaris. A follow-up study of 57 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196748" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pityriasis rubra pilaris in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26963004" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra Pilaris: A Case Series of 100 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18819727" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30520557" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Systemic therapies of pityriasis rubra pilaris: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32293641" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31789274" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment of pityriasis rubra pilaris type I: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29335741" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Methotrexate Treatment for Pityriasis Rubra Pilaris: A Case Series and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28122069" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36167251" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pityriasis Rubra Pilaris Transcriptomics Implicate T Helper 17 Signaling and Correlate with Response to Ixekizumab, with Distinct Gene Expression Profiles in Nonresponders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35701384" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30345340" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Transformation from pityriasis rubra pilaris to erythema gyratum repens-like eruption without associated malignancy: A report of 2 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32441433" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Successful treatment of resistant pityriasis rubra pilaris with ixekizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30827945" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Successful treatment of TNFαinhibitor-resistant pityriasis rubra pilaris with ixekizumab and acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30246123" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Successful treatment of type I pityriasis rubra pilaris with ixekizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29867429" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32185430" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : [Pityriasis rubra pilaris : Successful treatment with ixekizumab].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33179881" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Secukinumab is an effective and safe treatment for refractory pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32725719" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31260082" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29984296" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29894526" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27981219" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Successful treatment of type II pityriasis rubra pilaris with secukinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27706476" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33128453" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Response of pityriasis rubra pilaris to brodalumab after primary failure to ustekinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32202311" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Familial pityriasis rubra pilaris successfully treated with brodalumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31851372" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Successful treatment of Pityriasis rubra pilaris with brodalumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31397958" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Patient experiences with biologics and apremilast in pityriasis rubra pilaris: A patient survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33274752" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33973380" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of pityriasis rubra pilaris with risankizumab in two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33914925" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risankizumab for pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34101231" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Refractory Type I pityriasis rubra pilaris treated with tildrakizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31917873" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7040513" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10354036" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8547057" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pityriasis rubra pilaris and human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29477734" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32349169" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical response to ustekinumab in CARD14-associated papulosquamous eruption (CAPE) with a new missense mutation in CARD14: a case report and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34075616" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : CARD14-associated papulosquamous eruption (CAPE) in a toddler responding to treatment with acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29609014" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Biologics for pityriasis rubra pilaris treatment: A review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233350" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bath-PUVA as a treatment for Pityriasis rubra pilaris provoked by ultraviolet B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11251596" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Phototesting and phototherapy in pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35895853" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
